Press releases

Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016

ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016

Oryzon Initiates Multiple Ascending Dose Cohorts In ORY-2001 Phase 1 Clinical Trial

Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

ORYZON to Present at the JMP Securities Life Sciences Conference on June 22nd, 2016

EpigenomicsNet features Oryzon CSO Tamara Maes on Epigenetic drug development

ORYZON to extend its R&D collaboration on ORY-1001 until March 2017

ORYZON Reports First Quarter 2016 Financial Results and Corporate Update

ORYZON Closes € 10.5 Million (12.1 M USD) Debt Financing

Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans